Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Esslingen am Neckar
Clinical trial register · Germany

Clinical Trials in Esslingen am Neckar, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 20 Oct 2026, 03:18 UTC
5062
Studies in scope
all four open statuses
2873
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1586 Hamburg 889 Essen 766 Dresden 716 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca5 Daiichi Sankyo4 Bristol-Myers Squibb4 Gilead Sciences3 Hoffmann-La Roche3
Site location
Berlin1586 Hamburg889 Essen766 Dresden716 Heidelberg627
All 639 locations
Target enrolment
to

Trials with a site in Esslingen am Neckar

50 of 5062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Women's Cancer Study Group GmbH
Phase 3
1,520
Mannheim, Tübingen, Esslingen am Neckar, Freiburg im Breisgau, Amberg, Augsburg, München, Würzburg
2026-04-29
Recruiting
Boehringer Ingelheim
Phase 3
400
Berlin, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Heidelberg, Oldenburg
2026-01-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Esslingen am Neckar, Stuttgart, Donauwörth, Oldenburg, Cologne, Chemnitz, Kiel, Berlin
2025-11-05
Recruiting
Hoffmann-La Roche
Phase 3
600
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Essen, Esslingen am Neckar, Manheim, Nordrhein Westfalen
2025-10-24
Recruiting
CatalYm GmbH
Phase 2
131
Esslingen am Neckar, Heidelberg, Würzburg, Bielefeld, Essen, Moers
2025-10-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Esslingen am Neckar, Augsburg, München, Frankfurt am Main, Langen, Hanover, Düsseldorf, Essen
2025-09-11
Recruiting
GlaxoSmithKline
Phase 3
420
Karlsruhe, Löwenstein, Stuttgart, Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Lübeck
2025-08-11
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Berlin, Esslingen am Neckar, Großhansdorf, Immenhausen, Velbert
2025-07-17
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Esslingen am Neckar, Ulm, München, Frankfurt am Main, Giessen, Hanover, Oldenburg, Cologne
2025-04-24
Recruiting
Gilead Sciences
Phase 3
695
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Hamburg, Löwenstein, Minden, Munich
2025-04-04
Recruiting
Summit Therapeutics
Phase 3
780
Chemnitz, Esslingen am Neckar, Gauting, Giesen, Halle, Herne, Karlsruhe, Minden
2025-02-27
Recruiting
BioNTech SE
Phase 3
621
Berlin, Bonn, Chemnitz, Esslingen am Neckar, Gauting, Gera, Großhansdorf, Halle
2025-02-03
Recruiting
BioNTech SE
Phase 2/3
1,580
Aachen, Berlin, Chemnitz, Düsseldorf, Erlangen, Esslingen am Neckar, Gauting, Gera
2025-01-07
Recruiting
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt
2024-11-27
Active, closed
Genmab
Phase 3
191
Esslingen am Neckar, Heidelberg, Göttingen, Hanover, Mainz, Dresden, Halle, Großhansdorf
2024-11-25
Recruiting
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Essen, Esslingen am Neckar
2024-11-18
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Esslingen am Neckar, Ulm, Kempten (Allgäu), München, Marburg, Hanover, Dortmund, Herne
2024-10-07
Active, closed
Hoffmann-La Roche
Phase 3
338
Berlin, Cologne, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Heidelberg, Hemer
2024-09-23
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Immenhausen, Essen, Großhansdorf, Esslingen am Neckar, Giessen, Hamburg, Hemer, Neuss
2024-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Esslingen am Neckar, Regensburg, Hemer, Koblenz, Leipzig, Halle, Bad Berka, Gera
2024-04-03
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Halle, Bonn, Esslingen am Neckar, Frankfurt a.M., Gauting, Großhansdorf, Heidelberg
2024-02-21
Active, closed
Bristol-Myers Squibb
Phase 3
190
Esslingen am Neckar, Würzburg, Oldenburg, Berlin, Cologne, Dresden, Gauting, Immenhausen
2023-12-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Esslingen am Neckar, Gauting, Kempten (Allgäu), Regensburg, Bochum, Münster, Paderborn, Großhansdorf
2023-12-06
Active, closed
AstraZeneca
Phase 3
1,902
Augsburg, Berlin, Dessau, Dresden, Erlangen, Essen, Esslingen am Neckar, Frankfurt am Main
2023-11-14
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
Cologne, Esslingen am Neckar, Moers, Nuremberg
2023-11-14
Active, closed
Summit Therapeutics
Phase 3
1,600
Esslingen am Neckar, Frankfurt, Gauting, Giesen, Heidelberg, Jena, Kempten, Lübeck
2023-10-26
Active, closed
Hoffmann-La Roche
Phase 3
687
Esslingen am Neckar, Magdeburg, Mainz, Tübingen
2023-09-14
Active, closed
OncoC4, Inc.
Phase 3
630
Bogenhausen, Essen, Esslingen am Neckar, Immenhausen, Immenstädt, Muenchen-Gauting
2023-06-28
Active, closed
AbbVie
Phase 3
520
Esslingen am Neckar, Heidelberg, Erlangen, Giessen, Bielefeld, Bonn, Dortmund, Mainz
2023-03-15
Active, closed
Daiichi Sankyo
Phase 3
1,170
Berlin, Chemnitz, Essen, Esslingen am Neckar, Freiburg im Breisgau, Giessen, Mannheim, Munich
2023-01-11
Active, closed
Daiichi Sankyo
Phase 3
586
Essen, Esslingen am Neckar, Frankfurt am Main, Gauting, Giessen, Großhansdorf, Heidelberg, Immenhausen
2022-07-08
Active, closed
Gilead Sciences
Phase 2
193
Berlin, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Halle
2022-05-30
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
27
Bad Saarow, Berlin, Bonn, Cologne, Esslingen am Neckar, Frankfurt, Hanover, Krefeld
2022-04-20
Active, closed
Daiichi Sankyo
Phase 3
740
Berlin, Esslingen am Neckar, Großhansdorf, München
2022-03-04
Active, closed
AstraZeneca
Phase 3
390
Berlin, Esslingen am Neckar, Georgsmarienhütte, Lübeck, München, Würzburg
2022-02-21
Active, closed
AstraZeneca
Phase 3
1,051
Erfurt, Erlangen, Essen, Esslingen am Neckar, Georgsmarienhütte, Gütersloh, Hanover, Oldenburg
2022-02-07
Active, closed
Gilead Sciences
Phase 3
603
Braunschweig, Esslingen am Neckar, Hamburg, Heilbronn, Immenhausen, Kassel, Lübeck, Mannheim
2021-11-17
Active, closed
Prof. Dr. med. Claus Rödel
Phase 3
702
Esslingen am Neckar, Freiburg im Breisgau, Mannheim, Mutlangen, Offenburg, Ostfildern, Stuttgart, Tübingen
2020-11-05
Recruiting
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04111978Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC)
DrugLetrozole
Swiss GO Trial Group
Phase 3
540
Berlin, Cologne, Deggendorf, Dresden, Düsseldorf, Essen, Esslingen am Neckar, Freiburg im Breisgau
2020-11-05
Active, closed
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565HER2-negative Breast Cancer, Triple Negative Breast Cancer
DrugsXeloda·Sacituzumab Govitecan·Paraplatin·Capecitabine
GBG Forschungs GmbH
Phase 3
1,332
Böblingen, Esslingen am Neckar, Freiburg im Breisgau, Karlsruhe, Mannheim, Nürtingen, Reutlingen, Ulm
2020-10-28
Active, closed
German CLL Study Group
Phase 2
42
Augsburg, Cologne, Esslingen am Neckar, Hamm, Homburg, Kiel, Mönchengladbach, Munich
2020-10-01
Recruiting
Takeda
Phase 2
210
Bayreuth, Berlin, Bonn, Düsseldorf, Esslingen am Neckar, Halle, Leipzig, Mainz
2020-08-19
Recruiting
European Breast Cancer Research Association of Surgical Trialists
Observational
3,000
Esslingen am Neckar
2020-04-28
Active, closed
University Hospital Tuebingen
Phase 3
1,065
Amberg, Augsburg, Bad Kreuznach, Bremen, Dresden, Düsseldorf, Erfurt, Esslingen am Neckar
2018-07-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Esslingen am Neckar, Immenhausen, Düsseldorf, Hemer, Rheine, Koblenz, Dresden, Leipzig
2018-04-24
Recruiting
Klinikum Esslingen
Observational
50
Esslingen am Neckar
2017-12-15
Active, closed
National Cancer Institute (NCI)
Phase 3
712
Dresden, Berlin, Bochum, Cologne, Esslingen am Neckar, Hamburg, Leipzig, Mannheim
2017-10-16
Active, closed
European LeukemiaNet
Phase 2
75
Freiburg im Breisgau, Mannheim, München, Hannover, Aachen, Bayreuth, Chemnitz, Esslingen am Neckar
2016-09
Active, closed
Universitätsklinikum Hamburg-Eppendorf
Phase 3
789
Hamburg, Aachen, Berlin, Dresden, Essen, Esslingen am Neckar, Frankfurt, Freiburg im Breisgau
2014-04
Rows per page Showing 1–50 of 50
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-germany/city/esslingen-am-neckar

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 20 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 50 of those studies with a site in Esslingen am Neckar.

How many clinical trials are recruiting in Esslingen am Neckar?

23 of the 50 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Esslingen am Neckar), 50 studies
PhaseStudiesRecruitingShare
Phase 3371574%
Phase 27214%
Phase 2/3336%
Observational224%
Phase 1/2112%

Most active sponsors

Lead sponsors with the most studies (Esslingen am Neckar)
Lead sponsorStudiesRecruiting
AstraZeneca52
Bristol-Myers Squibb43
Daiichi Sankyo41
Gilead Sciences31
Hoffmann-La Roche31
Merck Sharp & Dohme LLC31
BioNTech SE22
Summit Therapeutics21
AbbVie10
Boehringer Ingelheim11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.